UBS Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $111
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma initiates coverage on Axsome Therapeutics (AXSM) with a Buy rating and a price target of $111.
February 06, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS initiated coverage on Axsome Therapeutics with a Buy rating and a price target of $111.
The initiation of coverage by a major financial institution like UBS, especially with a Buy rating and a significant price target, is likely to generate positive sentiment among investors. This could lead to increased buying activity in the short term, pushing the stock price up.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100